Alveus Therapeutics

Based in the US, Alveus Therapeutics focuses on developing innovative therapeutic solutions for obesity and metabolic diseases, with a specialized portfolio targeting effective weight management. Alveus Therapeutics, founded in 2023 and headquartered in Philadelphia, US, is dedicated to developing advanced therapies for obesity and related conditions. The company has secured a total of USD 159. 80 mn through its Series A funding, which it will utilize to accelerate the Phase 2 development of its lead product, ALV-100.

The funding round was co-led by Andera Partners, Avego Healthcare Capital, Kurma Partners, New Rhein Healthcare Investors, Omega Funds, and Sanofi Ventures. Alveus has conducted one deal, with the latest funding round closing on January 8, 2026. The firm was founded by a team of individuals, though specific details regarding their previous ventures are not disclosed. Alveus Therapeutics specializes in developing advanced therapeutic solutions aimed at addressing obesity and related metabolic diseases.

The company’s primary focus is on a differentiated portfolio of next-generation metabolic therapies, with its lead asset, ALV-100, currently in Phase 2 clinical trials. This therapeutic candidate is designed to promote sustainable weight loss while ensuring superior tolerability for patients—a critical challenge in the obesity treatment landscape. Additionally, Alveus is advancing a preclinical pipeline of amylin-based therapies, which includes best-in-class peptides, oral small molecules, and innovative formats that target optimal weight loss quality. These products primarily cater to healthcare providers and patients in North America and Europe, particularly focusing on markets where obesity and metabolic diseases are prevalent.

Alveus Therapeutics has recently secured USD 159. 80 mn in Series A financing, a strategic move that underscores its commitment to advancing its therapeutic offerings for obesity and metabolic diseases. The company’s revenue generation model is rooted in partnerships with healthcare organizations and pharmaceutical firms, which may include licensing agreements or collaborations for the development and distribution of its products. Transactions typically involve structured agreements that align with the milestones of clinical development, wherein partners may provide funding in exchange for access to novel therapies.

The firm’s flagship product, ALV-100, represents a significant focus in these agreements, potentially leading to revenue streams derived from both clinical trial sponsorships and future commercialization efforts upon successful regulatory approvals. In January 2026, Alveus Therapeutics raised USD 197 mn in Series A funding, which will be utilized to advance the Phase 2 development of ALV-100 and to file IND applications for ALV-200. The company is also progressing additional R&D programs aimed at enhancing its portfolio. Alveus plans to expand its presence in markets across North America and Europe, with a focus on delivering innovative treatments for obesity and metabolic diseases by leveraging recent funding to accelerate product development and market entry.